Catalog No.: PC-24862Not For Human Use, Lab Use Only.
MT-125 is a specific, brain penetrant small-molecule inhibitor of non-muscle myosin IIA and IIB (NMIIA and IIB) with Ki of 2.7 uM (NMIIA) and EC50 of 1.7 uM (NMIIB).
MT-125 is a specific, brain penetrant small-molecule inhibitor of non-muscle myosin IIA and IIB (NMIIA and IIB) with Ki of 2.7 uM (NMIIA) and EC50 of 1.7 uM (NMIIB).
MT-125 has very limited activity against cardiac myosin II (CMII; KI,CMII = 50 uM).
MT-125 blocks GBM invasion and cytokinesis, and prolongs survival in murine GBM models.
MT-125 increases redox stress and consequent DNA damage, and synergizes with radiotherapy.
MT-125 also induces oncogene addiction to PDGFR signaling through a mechanism that is driven by redox stress, and it synergizes with FDA-approved PDGFR and mTOR inhibitors in vitro.
Combining MT-125 with sunitinib, a PDGFR inhibitor, or paxalisib, a combined phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitor, significantly improves survival in orthotopic GBM models over either drug alone.
